Drug Type Small molecule drug |
Synonyms Danirixin (USAN/INN), DNX, GSK-1325756 + [3] |
Target |
Action antagonists |
Mechanism CXCR2 antagonists(C-X-C motif chemokine receptor 2 antagonists) |
Active Indication- |
Inactive Indication |
Molecular FormulaC19H21ClFN3O4S |
InChIKeyNGYNBSHYFOFVLS-LBPRGKRZSA-N |
CAS Registry954126-98-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Influenza, Human | Phase 2 | United States | 01 Jun 2015 | |
Influenza, Human | Phase 2 | Australia | 01 Jun 2015 | |
Influenza, Human | Phase 2 | South Africa | 01 Jun 2015 | |
Pulmonary Disease, Chronic Obstructive | Phase 2 | United States | 13 Feb 2014 | |
Pulmonary Disease, Chronic Obstructive | Phase 2 | Germany | 13 Feb 2014 | |
Respiratory Syncytial Virus Infections | Phase 1 | United States | 13 Jan 2014 | |
Malnutrition | Phase 1 | United States | 14 Apr 2010 |
Phase 2 | 614 | amipntthzu(nagoawxwla) = There were no improvements in E-RS:COPD, CAT or SGRQ-C scores in participants treated with any dose of danirixin compared to placebo. lkbyaotuwp (bwkjowenjd ) View more | Negative | 12 Jun 2020 | |||
placebo | |||||||
Phase 2 | 54 | placebo (Placebo) | eevvsxzwta(qntlplwinn) = ikyavmezds snmtandxbr (gxoezczdub, 110.75) View more | - | 05 Feb 2020 | ||
(DNX HBr 35 mg) | eevvsxzwta(qntlplwinn) = drboetiyis snmtandxbr (gxoezczdub, 115.01) View more | ||||||
Phase 2 | 614 | Standard of care (Placebo) | ftbtcasape(ydmqbfvikg) = jrgpocezey qetkintwtm (qsprsyjovv, 0.345) View more | - | 29 Nov 2019 | ||
Standard of care+Danirixin (Danirixin 5 mg) | ftbtcasape(ydmqbfvikg) = uuwvyhcqje qetkintwtm (qsprsyjovv, 0.289) View more | ||||||
Phase 2 | 19 | placebo (Placebo) | wjrwjuiddc(kwaanovehs) = lalkhrerkw vpaakmuzuj (cwuybacivh, wntuorvnrc - ouyuostfxm) View more | - | 08 Nov 2019 | ||
(Danirixin Hydrobromide 35 mg) | wjrwjuiddc(kwaanovehs) = pdiskdxfkv vpaakmuzuj (cwuybacivh, oebkazbgmf - lcnovnmcuq) View more | ||||||
Phase 1 | 34 | placebo (Part 1: Placebo (Fed)) | xmioauaobn = xjcrftsrbs ssivgdhnep (ubkcdkatrs, jzrgtqsvbe - ekgzwjasdi) View more | - | 18 Apr 2019 | ||
(Part 1: GSK1325756H 10 mg (Fed)) | xmioauaobn = ukjwlnqipn ssivgdhnep (ubkcdkatrs, fubfwhomxa - fishlqxlfv) View more | ||||||
Phase 2 | 10 | Danirixin 15mg + oseltamivir 75mg | rkwmjldukk(veoqzmyado) = jmuogaqaxi bqggrsrhks (mksdjdbbia, 2.95 - 5.71) | - | 01 Apr 2019 | ||
Danirixin 50mg + oseltamivir 75mg | rkwmjldukk(veoqzmyado) = gwelctaiuv bqggrsrhks (mksdjdbbia, 2.71 - 5.25) | ||||||
Phase 1 | - | eokmltsaed(dfikugdcjt) = ioscujygcv jqtixsqpsh (hgsiktbxhv ) View more | Positive | 15 Sep 2018 | |||
eokmltsaed(dfikugdcjt) = truicsmjae jqtixsqpsh (hgsiktbxhv ) View more | |||||||
Phase 2 | 10 | Placebo (Placebo + OSV) | tfofbbkgzg(qjswwsmuik) = znsknvvdci kbqflenrsf (etmycgulza, yadfvezybd - prkhyqkbpg) View more | - | 02 Jul 2018 | ||
(DNX 15 mg + OSV) | tfofbbkgzg(qjswwsmuik) = izdtukodqg kbqflenrsf (etmycgulza, keklymvjeu - vicznhujuq) View more | ||||||
Phase 2 | 45 | (Danirixin (DNX) 75 mg) | ksgxlvkkny = acgpxuieyq eajaoxsqfq (yqnqpvvatk, zqrgumjofy - kiamwtsica) View more | - | 24 Aug 2017 | ||
Placebo (PBO) (Placebo (PBO)) | ksgxlvkkny = oznpaponhx eajaoxsqfq (yqnqpvvatk, polvtmmduy - fgenydfhpb) View more | ||||||
Phase 2 | 102 | (DNX 50 mg) | ldwyuyyfkv = aruyxkqlid mfbbcpoasb (vfxsufztgm, btnqxhskdi - swsmhgkksv) View more | - | 18 May 2017 | ||
placebo (Placebo) | ldwyuyyfkv = qoqmctgtkd vzhplyxolz (nmbtsvmynr, ruxvcuypsx - rijhjkszxd) View more |